Sustainable results: Weight loss achieved with GLP-1 therapy tends to be gradual, averaging 13lbs per week, which is optimal for long-term maintenance
28,29 While not associated with clinical benefit in HFrEF, recently, these drugs have been studied in patients with HFpEF demonstrating improvements in clinical outcomes such as health-related quality of life (STEP-HFpEF) as well as reductions in cardiovascular death and HF events (SUMMIT)
Novos uncharacteristic reticence on this legal strategy casts light on its potential drawbacks
Combining these can lead to severe nutrient deficiencies, muscle loss, and an increased risk of gallstones
Peng, C
Earlier incretin-based medicines focused mainly on GLP-1 receptor signaling, while newer investigational compounds explore whether combining GLP-1, GIP, and glucagon pathways can produce distinct metabolic effects